Dabigatran | Rivaroxaban | |||
Variable | OR (95% CI) | p Value | OR (95% CI) | p Value |
Age (reference>75 years) | 0.98 (0.90 to 1.06) | 0.61 | 0.96 (0.85 to 1.08) | 0.47 |
Sex (reference female) | 1.08 (1.01 to 1.16) | 0.02 | 1.18 (1.08 to 1.30) | <0.001 |
Rural residence (vs urban) | 0.96 (0.87 to 1.06) | 0.39 | 0.86 (0.75 to 0.99) | 0.04 |
University education | 1.09 (0.97 to 1.22) | 0.16 | 0.98 (0.83 to 1.15) | 0.80 |
Prior warfarin use | 0.96 (0.90 to 1.03) | 0.26 | 0.86 (0.78 to 0.95) | 0.02 |
High-risk CHADS2 (vs low risk) | 0.90 (0.77 to 1.06) | 0.21 | 1.07 (0.85 to 1.35) | 0.57 |
Moderate-risk CHADS2 (vs low risk) | 0.98 (0.86 to 1.12) | 0.79 | 1.10 (0.91 to 1.33) | 0.35 |
Hypertension | 1.01 (0.93 to 1.10) | 0.85 | 0.98 (0.87 to 1.11) | 0.81 |
Diabetes | 0.95 (0.88 to 1.03) | 0.24 | 0.97 (0.86 to 1.09) | 0.63 |
Coronary artery disease | 0.96 (0.90 to 1.04) | 0.33 | 0.91 (0.82 to 1.01) | 0.07 |
Chronic kidney disease | 1.15 (0.97 to 1.36) | 0.11 | 1.17 (0.95 to 1.44) | 0.15 |
History of bleeding | 1.04 (0.95 to 1.15) | 0.38 | 0.94 (0.82 to 1.08) | 0.40 |
Stroke/TIA | 1.00 (0.89 to 1.13) | 0.94 | 0.84 (0.70 to 1.00) | 0.05 |
Cardiologist vs generalist | 0.98 (0.89 to 1.09) | 0.77 | 1.12 (0.97 to 1.29) | 0.13 |
Internist vs generalist | 1.07 (0.98 to 1.17) | 0.15 | 1.17 (1.03 to 1.33) | 0.01 |
Other physician type vs generalist | 1.09 (0.98 to 1.20) | 0.10 | 1.11 (0.96 to 1.28) | 0.17 |
CHADS2, congestive heart failure, hypertension, age, diabetes, stroke; TIA: transient ischaemic attack.